Collaboration across borders to unleash the potential of our pipeline assets
Our BD&L team, formed by professionals with years of business development experience, is responsible for initiating various partnerships. Currently, our in-licensing efforts are focused on Endocrine, Metabolic and Cardiovascular Disorders, with a special emphasis on Women’s Health, to synergize with HopeMed’s scientific expertise and broad clinical network.
Current Collaborators
-
Bayer
Hope Medicine entered into a global license agreement with Bayer to advance the development and commercialization of the monoclonal antibody directed against prolactin (PRL) receptor in 2019.
-
Nanjing JiangBei New Area
With the strong support and help from the Nanjing JiangBei New Area, Hope Medicine (Nanjing) Co., Ltd. was founded and registered in JiangBei, and the Biological R&D center of the company was officially launched in Nanjing Bio-tech and Pharmaceutical Valley of JiangBei New Area in October 2021.
-
Peking University
Hope Medicine has established a diversified research portfolio based on the founder, Professor Xiao's breakthrough research at the Institute of Molecular Medicine (IMM) at Peking University via a joint research lab, with a strong translational focus, for a continuous innovative early discovery pipeline.
-
Lonza (GZB)
Lonza Guangzhou facility (GZB) supports HMI-115 Drug Substance process tech transfer and clinical supply for HopeMed Ph1/2 global MRCT.
-
WuXi Biologics
Manufactures HMI115 Drug Product and Placebo to support HopeMed Ph1/2 global MRCT.
-
Parexel
HopeMedicine entered a collaboration with Parexel, one of the world's leading global clinical research organizations (CRO), to support global clinical study of HMI-115.
-
dMed-Clinipace
Hope Medicine entered collaborations with dMed-Clinipace for clinical development of HMI-115 in Asia Pacific region.
